Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | GBA1 | P04062 | 12/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12265820 | 1.00 | HRH4 (0.55) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL18493347 | 0.99 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL22762136 | 0.99 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL18489275 | 0.99 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL19479091 | 0.99 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL18494157 | 0.99 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL19300362 | 0.99 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL18488738 | 0.95 | HRH4 (0.53) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL20375486 | 0.95 | HRH4 (0.56) | HRH4HRH3GBA1EPHX2CYP19A1 | |
| SCHEMBL18789724 | 0.95 | GBA1 (0.54) | HRH4HRH3GBA1EPHX2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3301108-A1 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20130072439-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | HRH4 1851/4885HRH3 2016/4885GBA1 669/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | HRH4 4460/4885HRH3 3972/4885GBA1 280/4885 |
| US-20130072439-A1 | PEPTIDOMIMETIC MACROCYCLES | TCF4, WNT1, CTNNB1 | HRH4 1310/4885HRH3 2149/4885GBA1 4683/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | HRH4 2978/4885HRH3 2750/4885GBA1 998/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | HRH4 1851/4885HRH3 2016/4885GBA1 669/4885 |
| US-20120149648-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | HRH4 3022/4885HRH3 2281/4885GBA1 2876/4885 |
| US-20170114098-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | NGLY1, BID, DNPEP | HRH4 2561/4885HRH3 2159/4885GBA1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.